About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Global Short-Acting Insulin Market Size, Top Share, Industry Trends, Report 2030
Short-Acting Insulin Market

Short-Acting Insulin Market Size, Share & Trends Analysis Report By Drug (Novolog, Humalog, Humulin) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Report Code: SRHI1680DR
Last Updated : August 08, 2024
Author : Straits Research
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Short-Acting Insulin Market Introduction
    2. By Drug
      1. Introduction
        1. Drug By Value
      2. Novolog
        1. By Value
      3. Humalog
        1. By Value
      4. Humulin
        1. By Value
    1. Introduction
    2. By Drug
      1. Introduction
        1. Drug By Value
      2. Novolog
        1. By Value
      3. Humalog
        1. By Value
      4. Humulin
        1. By Value
    3. U.S.
      1. By Drug
        1. Introduction
          1. Drug By Value
        2. Novolog
          1. By Value
        3. Humalog
          1. By Value
        4. Humulin
          1. By Value
    4. Canada
    1. Introduction
    2. By Drug
      1. Introduction
        1. Drug By Value
      2. Novolog
        1. By Value
      3. Humalog
        1. By Value
      4. Humulin
        1. By Value
    3. U.K.
      1. By Drug
        1. Introduction
          1. Drug By Value
        2. Novolog
          1. By Value
        3. Humalog
          1. By Value
        4. Humulin
          1. By Value
    4. Germany
    5. France
    6. Spain
    7. Italy
    8. Russia
    9. Nordic
    10. Benelux
    11. Rest of Europe
    1. Introduction
    2. By Drug
      1. Introduction
        1. Drug By Value
      2. Novolog
        1. By Value
      3. Humalog
        1. By Value
      4. Humulin
        1. By Value
    3. China
      1. By Drug
        1. Introduction
          1. Drug By Value
        2. Novolog
          1. By Value
        3. Humalog
          1. By Value
        4. Humulin
          1. By Value
    4. Korea
    5. Japan
    6. India
    7. Australia
    8. Taiwan
    9. South East Asia
    10. Rest of Asia-Pacific
    1. Introduction
    2. By Drug
      1. Introduction
        1. Drug By Value
      2. Novolog
        1. By Value
      3. Humalog
        1. By Value
      4. Humulin
        1. By Value
    3. UAE
      1. By Drug
        1. Introduction
          1. Drug By Value
        2. Novolog
          1. By Value
        3. Humalog
          1. By Value
        4. Humulin
          1. By Value
    4. Turkey
    5. Saudi Arabia
    6. South Africa
    7. Egypt
    8. Nigeria
    9. Rest of MEA
    1. Introduction
    2. By Drug
      1. Introduction
        1. Drug By Value
      2. Novolog
        1. By Value
      3. Humalog
        1. By Value
      4. Humulin
        1. By Value
    3. Brazil
      1. By Drug
        1. Introduction
          1. Drug By Value
        2. Novolog
          1. By Value
        3. Humalog
          1. By Value
        4. Humulin
          1. By Value
    4. Mexico
    5. Argentina
    6. Chile
    7. Colombia
    8. Rest of LATAM
    1. Short-Acting Insulin Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Novo Nordisk AS
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Sanofi
    3. Eli Lilly and Company
    4. Verily
    5. Sensile
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The global rapid-acting insulin market size was valued at USD 6.77 billion in 2021. It is expected to reach USD 9.72 billion by 2030, growing at a CAGR of 4.1% during the forecast period (2022–2030). Insulin analogs classified as rapid-act
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.